The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

Treatment of Advanced Hodgkin Lymphoma

진행성 호지킨 림프종의 치료

  • Kim, Sung-Yong (Division of Hemato-Oncology, Department of Internal Medicine, KonKuk University School of Medicine)
  • 김성용 (건국대학교 의학전문대학원 내과학교실 종양혈액내과)
  • Published : 2011.11.01
⟨ Previous Next ⟩

Abstract

The major portion of Hodgkin lymphoma (HL) patients, even at an advanced stage can be cured with optimal initial treatment. ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) is the standard treatment regimen for the advanced stage HL, while Stanford V (doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, and prednisone) and escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) can be reasonable alternatives for selected patients. Although radiotherapy is the key component in Stanford V regimen, radiotherapy should be applied only at the residual lymphoma in patients who received ABVD and BEACOPP therapy. These three representative treatments for advanced HL have individual advantages and disadvantages, so that the choice of the initial treatment should be dependent on patients' relapse risk, comorbidity, and age.

Keywords

References

  1. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease: international prognostic factors project on advanced Hodgkin's disease. N Engl J Med 1998;339:1506-1514. https://doi.org/10.1056/NEJM199811193392104
  2. Hoskin PJ, Lowry L, Horwich A, et al. Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. J Clin Oncol 2009;27:5390-5396. https://doi.org/10.1200/JCO.2009.23.3239
  3. Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. J Clin Oncol 2009;27:805-811. https://doi.org/10.1200/JCO.2008.17.0910
  4. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hodgikin Lymphoma. [Version 3.2011]. PA: NCCN; 2011.
  5. Engert A, Eichenauer DA, Dreyling M; ESMO Guidelines Working Group. Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(Suppl 4):S108-S109.
  6. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586. https://doi.org/10.1200/JCO.2006.09.2403
  7. Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975;36:252-259. https://doi.org/10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7
  8. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003;21:607-614. https://doi.org/10.1200/JCO.2003.12.086
  9. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478-1484. https://doi.org/10.1056/NEJM199211193272102
  10. Somers R, Carde P, Henry-Amar M, et al. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol 1994;12:279-287.
  11. Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 2005;23:7614-7620. https://doi.org/10.1200/JCO.2005.02.7243
  12. Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 2007;99:206-214. https://doi.org/10.1093/jnci/djk029
  13. Viviani S, Santoro A, Ragni G, Bonfante V, Bestetti O, Bonadonna G. Gonadal toxicity after combination chemotherapy for Hodgkin's disease: comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol 1985;21:601-605. https://doi.org/10.1016/0277-5379(85)90088-4
  14. Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ. Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report. J Clin Oncol 1995;13:1080-1088.
  15. Horning SJ, Williams J, Bartlett NL, et al. Assessment of the stanford V regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: Eastern Cooperative Oncology Group pilot study E1492. J Clin Oncol 2000;18:972-980.
  16. Gobbi PG, Levis A, Chisesi T, et al. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 2005;23:9198-9207. https://doi.org/10.1200/JCO.2005.02.907
  17. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPPABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348:2386-2395. https://doi.org/10.1056/NEJMoa022473
  18. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 Study. J Clin Oncol 2009;27:4548-4554. https://doi.org/10.1200/JCO.2008.19.8820
  19. Dann EJ, Bar-Shalom R, Tamir A, et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007;109:905-909.
  20. Ballova V, Rüffer JU, Haverkamp H, et al. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 2005;16:124-131. https://doi.org/10.1093/annonc/mdi023
  21. Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med 2011;365:203-212. https://doi.org/10.1056/NEJMoa1100340
  22. Fabian CJ, Mansfield CM, Dahlberg S, et al. Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease: aSouthwest Oncology Group randomized study. Ann Intern Med 1994;120:903-912. https://doi.org/10.7326/0003-4819-120-11-199406010-00002
  23. Ferme C, Sebban C, Hennequin C, et al. Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: results of the groupe d'etudes des lymphomes de l'Adulte H89 trial. Blood 2000;95:2246-2252.
  24. Laskar S, Gupta T, Vimal S, et al. Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? J Clin Oncol 2004;22:62-68.
  25. Loeffler M, Brosteanu O, Hasenclever D, et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease:International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol 1998;16:818-829.
  26. Aleman BM, Raemaekers JM, Tomiŝiĉ R, et al. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2007;67:19-30. https://doi.org/10.1016/j.ijrobp.2006.08.041
  27. Federico M, Bellei M, Brice P, et al. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol 2003;21:2320-2325. https://doi.org/10.1200/JCO.2003.11.103
  28. Maeda LS, Advani RH. The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma. Curr Opin Oncol 2009;21:397-400. https://doi.org/10.1097/CCO.0b013e32832f3ca3
  29. Ekstrand BC, Lucas JB, Horwitz SM, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 2003;101:4285-4289. https://doi.org/10.1182/blood-2002-08-2644